Business Context and Reporting Period
Company: Grifols, S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2026 (H1 2026)
Filing Date: July 28, 2026
Grifols, a global healthcare company and leading producer of plasma-derived medicines, reported its first-half 2026 results. The company is executing a strategic transition toward a two-system operating model, separating U.S. and Rest of World (ROW) Biopharma operations to enhance regional plasma self-sufficiency. Key strategic initiatives include the expansion of plasma collection in Egypt and Canada, and the evaluation of a potential IPO for its U.S. Biopharma unit.
Key Financial Metrics
| Metric | H1 2026 | H1 2025 | Change (Constant Currency) |
|---|---|---|---|
| Net Revenue | €3,574 million | €3,677 million | +2.6% |
| Adjusted EBITDA | €854 million | €876 million | +2.4% |
| Adjusted EBITDA Margin | 23.9% | 23.8% | +10 bps |
| Group Profit | €227 million | €177 million | +28.7% |
| Free Cash Flow (pre-M&A) | €91 million | (€12 million) | €103 million improvement |
| Net Leverage Ratio | 4.2x | 4.2x | Stable |
| Liquidity | €2,030 million | €1,414 million | Increased |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue grew 2.6% at constant currency (cc), driven primarily by the Biopharma segment (+5.4% cc). The Immunoglobulin franchise grew 12.8% cc, led by strong demand for Gamunex (IVIG) and Xembify (SCIG). Conversely, Albumin revenue declined 14.2% cc due to pricing adjustments in China, and Diagnostics revenue fell 9.7% cc following the dissolution of the joint venture with QuidelOrtho.
- Profitability: Group profit increased significantly by 28.7% to €227 million, supported by the growth of the immunoglobulin franchise, the operational turnaround of Biotest, and disciplined operating expense management.
- Cash Flow: Free cash flow pre-M&A turned positive at €91 million, a €103 million year-over-year improvement from a negative €12 million in H1 2025. This was driven by improved working capital management and normalized CAPEX levels.
- Balance Sheet: Liquidity increased to €2,030 million. The company successfully refinanced all 2027 debt maturities and redeemed €500 million of its 2030 bond, extending the maturity profile with no significant maturities until Q4 2028.
Guidance, Outlook, and Risks
- Guidance: Grifols confirmed its full-year 2026 guidance, stating that H1 performance keeps the company on track to deliver its objectives. Key levers for the second half include continued immunoglobulin strength, the ramp-up of Egypt plasma collections, and further progress in the Biotest turnaround.
- Strategic Outlook: Management highlighted the evolution toward a two-system operating model (U.S. vs. ROW) to optimize sourcing costs and supply resilience. The Egypt joint venture is progressing, with the first phase of the industrial complex scheduled for inauguration in October 2026, aiming for 3 million liters of annual collection by 2029.
- Innovation Pipeline: The Phase 3 SPARTA study for alpha-1 antitrypsin is on track for top-line results in late Q4 2026. The company also launched FESILTY (fibrinogen) in the U.S. and advanced the Evanzys IH diagnostic platform.
- Risks and Contingencies:
- Regulatory/Tax: The company is subject to ongoing tax audits in Spain and the U.S. regarding transfer pricing and intercompany transactions. A provision of €203 million has been recognized for uncertain tax treatments.
- Operational: Risks include dependence on plasma supply (mitigated by Egypt/Canada projects), pricing pressure in key markets (China Albumin), and potential disruptions from geopolitical tensions.
- Legal: An administrative sanctioning procedure by the Spanish CNMV is ongoing, with a proposed sanction not exceeding €1 million.
Investor Verification Checklist
- China Albumin Pricing: Verify the stabilization of Albumin sales in China following the mid-2025 price adjustment and the impact on future margins.
- Egypt Project Timeline: Monitor the October 2026 inauguration of the Egypt industrial complex and the ramp-up of plasma collection volumes against the 2029 target of 3 million liters.
- Debt Refinancing Terms: Review the specific interest rate margins and covenants of the new €3 billion Term Loan B and the upsized $2 billion Revolving Credit Facility.
- U.S. Biopharma IPO: Track the progress of the evaluation for a potential minority IPO of the U.S. Biopharma unit, including regulatory approvals and market conditions.
- Tax Provision Resolution: Monitor the outcome of ongoing tax audits in Spain and the U.S., which could impact future cash flows and effective tax rates.